• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于结构的配体设计和片段筛选优化腺嘌呤 5'-羧酰胺衍生物作为腺苷受体激动剂。

Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

J Med Chem. 2012 May 10;55(9):4297-308. doi: 10.1021/jm300095s. Epub 2012 Apr 30.

DOI:10.1021/jm300095s
PMID:22486652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3479662/
Abstract

Structures of G protein-coupled receptors (GPCRs) have a proven utility in the discovery of new antagonists and inverse agonists modulating signaling of this important family of clinical targets. Applicability of active-state GPCR structures to virtual screening and rational optimization of agonists, however, remains to be assessed. In this study of adenosine 5' derivatives, we evaluated the performance of an agonist-bound A(2A) adenosine receptor (AR) structure in retrieval of known agonists and then employed the structure to screen for new fragments optimally fitting the corresponding subpocket. Biochemical and functional assays demonstrate high affinity of new derivatives that include polar heterocycles. The binding models also explain modest selectivity gain for some substituents toward the closely related A(1)AR subtype and the modified agonist efficacy of some of these ligands. The study suggests further applicability of in silico fragment screening to rational lead optimization in GPCRs.

摘要

G 蛋白偶联受体 (GPCR) 的结构已被证明可用于发现新的拮抗剂和反向激动剂,从而调节这一重要的临床靶标家族的信号转导。然而,激动剂的活性状态 GPCR 结构在虚拟筛选和合理优化中的适用性仍有待评估。在这项关于腺苷 5' 衍生物的研究中,我们评估了激动剂结合的 A(2A) 腺苷受体 (AR) 结构在检索已知激动剂方面的性能,然后利用该结构筛选与相应亚口袋最佳匹配的新片段。生化和功能测定表明,新衍生物具有高亲和力,其中包括极性杂环。结合模型还解释了一些取代基对密切相关的 A(1)AR 亚型的适度选择性增益,以及这些配体中一些的修饰激动剂效力。该研究表明,基于计算机的片段筛选在 GPCR 中的合理先导优化中具有进一步的适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/93b945ed12d6/nihms410853f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/9ea199650ce2/nihms410853f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/4d27d3145b33/nihms410853f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/ac192ec76896/nihms410853f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/24742c56cb02/nihms410853f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/939094a092bb/nihms410853f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/469e5dc91721/nihms410853f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/c596c79da470/nihms410853f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/93b945ed12d6/nihms410853f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/9ea199650ce2/nihms410853f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/4d27d3145b33/nihms410853f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/ac192ec76896/nihms410853f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/24742c56cb02/nihms410853f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/939094a092bb/nihms410853f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/469e5dc91721/nihms410853f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/c596c79da470/nihms410853f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a7/3479662/93b945ed12d6/nihms410853f8.jpg

相似文献

1
Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.基于结构的配体设计和片段筛选优化腺嘌呤 5'-羧酰胺衍生物作为腺苷受体激动剂。
J Med Chem. 2012 May 10;55(9):4297-308. doi: 10.1021/jm300095s. Epub 2012 Apr 30.
2
Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A adenosine receptor ligands.设计、合成及 2-肼基腺苷衍生物的生物评价作为 A 腺苷受体配体。
Eur J Med Chem. 2019 Oct 1;179:310-324. doi: 10.1016/j.ejmech.2019.06.050. Epub 2019 Jun 24.
3
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.激动剂结合的腺苷 A2A 受体结构揭示了 G 蛋白偶联受体激活的共同特征。
Nature. 2011 May 18;474(7352):521-5. doi: 10.1038/nature10136.
4
A and A adenosine receptors: The extracellular loop 2 determines high (A) or low affinity (A) for adenosine.A 和 A 腺苷受体:细胞外环 2 决定了对腺苷的高(A)或低亲和力(A)。
Biochem Pharmacol. 2020 Feb;172:113718. doi: 10.1016/j.bcp.2019.113718. Epub 2019 Nov 18.
5
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands.腺苷的N(6)-烷基-2-炔基衍生物作为人腺苷A(3)受体的强效和选择性激动剂以及寻找A(2B)配体的起点。
J Med Chem. 2002 Jul 18;45(15):3271-9. doi: 10.1021/jm0109762.
6
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.根据激动剂结合的 A₂A 腺苷受体晶体结构评估激动剂结合的分子建模。
J Med Chem. 2012 Jan 12;55(1):538-52. doi: 10.1021/jm201461q. Epub 2011 Dec 12.
7
Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands.腺苷受体配体的药效团模型和 3D QSAR 研究。
Curr Top Med Chem. 2010;10(10):1019-35. doi: 10.2174/156802610791293118.
8
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study.用于比较GPCR-配体对接协议性能的替代质量评估策略:以人类腺苷A(2A)受体为例进行研究
J Chem Inf Model. 2014 Aug 25;54(8):2243-54. doi: 10.1021/ci5002857. Epub 2014 Jul 31.
9
Medicinal chemistry of adenosine A2A receptor agonists.腺苷A2A受体激动剂的药物化学
Curr Top Med Chem. 2003;3(4):387-401. doi: 10.2174/1568026033392282.
10
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.A(3) 腺苷受体激活的结构决定因素:激动剂/拮抗剂边界处的核苷配体
J Med Chem. 2002 Sep 26;45(20):4471-84. doi: 10.1021/jm020211+.

引用本文的文献

1
The role of adenosine A receptor on immune cells.腺苷 A 受体在免疫细胞中的作用。
Inflamm Res. 2022 Nov;71(10-11):1203-1212. doi: 10.1007/s00011-022-01607-w. Epub 2022 Sep 5.
2
Spinal A adenosine receptor activation acutely restores morphine antinociception in opioid tolerant male rats.脊髓腺苷受体激动剂激活可急性恢复阿片耐受雄性大鼠的吗啡镇痛作用。
J Neurosci Res. 2022 Jan;100(1):251-264. doi: 10.1002/jnr.24869. Epub 2021 Jun 1.
3
Identification of Novel Chemical Entities for Adenosine Receptor Type 2A Using Molecular Modeling Approaches.利用分子建模方法鉴定腺苷受体 2A 的新型化学实体。
Molecules. 2020 Mar 10;25(5):1245. doi: 10.3390/molecules25051245.
4
Design and in Vivo Characterization of A Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.在天然核糖和构象受限(N)-甲羰桥环系列中设计和体内表征 A 腺苷受体激动剂。
J Med Chem. 2019 Feb 14;62(3):1502-1522. doi: 10.1021/acs.jmedchem.8b01662. Epub 2019 Jan 3.
5
Comparative Study of Carborane- and Phenyl-Modified Adenosine Derivatives as Ligands for the A2A and A3 Adenosine Receptors Based on a Rigid in Silico Docking and Radioligand Replacement Assay.基于刚性计算机对接和放射性配体替换测定的新型腺嘌呤衍生物作为 A2A 和 A3 腺苷受体配体的比较研究:碳硼烷和苯修饰物。
Molecules. 2018 Jul 25;23(8):1846. doi: 10.3390/molecules23081846.
6
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design.G蛋白偶联受体晶体学的突破及其对计算机辅助药物设计的影响。
Methods Mol Biol. 2018;1705:45-72. doi: 10.1007/978-1-4939-7465-8_3.
7
Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.核苷的支架重新利用(腺苷受体激动剂):对人多巴胺和去甲肾上腺素钠转运体的活性增强
J Med Chem. 2017 Apr 13;60(7):3109-3123. doi: 10.1021/acs.jmedchem.7b00141. Epub 2017 Mar 20.
8
Recent Advances and Applications of Molecular Docking to G Protein-Coupled Receptors.分子对接技术在G蛋白偶联受体中的最新进展与应用
Molecules. 2017 Feb 22;22(2):340. doi: 10.3390/molecules22020340.
9
Identification of Novel Smoothened Ligands Using Structure-Based Docking.基于结构对接识别新型Smoothened配体
PLoS One. 2016 Aug 4;11(8):e0160365. doi: 10.1371/journal.pone.0160365. eCollection 2016.
10
Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.旁系同源特异性Hsp90抑制剂——简要历史与光明未来
Curr Top Med Chem. 2016;16(25):2779-91. doi: 10.2174/1568026616666160413141154.

本文引用的文献

1
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.根据激动剂结合的 A₂A 腺苷受体晶体结构评估激动剂结合的分子建模。
J Med Chem. 2012 Jan 12;55(1):538-52. doi: 10.1021/jm201461q. Epub 2011 Dec 12.
2
Diversity and modularity of G protein-coupled receptor structures.G 蛋白偶联受体结构的多样性和模块化。
Trends Pharmacol Sci. 2012 Jan;33(1):17-27. doi: 10.1016/j.tips.2011.09.003. Epub 2011 Oct 25.
3
Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.基于晶体结构的人源组胺 H(1)受体配体的类片段虚拟筛选。
J Med Chem. 2011 Dec 8;54(23):8195-206. doi: 10.1021/jm2011589. Epub 2011 Nov 7.
4
Ligand discovery from a dopamine D3 receptor homology model and crystal structure.从多巴胺 D3 受体同源模型和晶体结构中发现配体。
Nat Chem Biol. 2011 Sep 18;7(11):769-78. doi: 10.1038/nchembio.662.
5
GPCR agonist binding revealed by modeling and crystallography.通过建模和晶体学揭示 G 蛋白偶联受体激动剂结合。
Trends Pharmacol Sci. 2011 Nov;32(11):637-43. doi: 10.1016/j.tips.2011.08.001. Epub 2011 Sep 6.
6
Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element.截短的(N)-甲碳环核苷作为A(1)腺苷受体激动剂和部分激动剂:克服识别元件缺失问题
ACS Med Chem Lett. 2011 Aug 11;2(8):626-631. doi: 10.1021/ml200114q.
7
Crystal structure of the β2 adrenergic receptor-Gs protein complex.β2 肾上腺素能受体-Gs 蛋白复合物的晶体结构。
Nature. 2011 Jul 19;477(7366):549-55. doi: 10.1038/nature10361.
8
Structure of the human histamine H1 receptor complex with doxepin.人源组胺 H1 受体复合物与多塞平的结构。
Nature. 2011 Jun 22;475(7354):65-70. doi: 10.1038/nature10236.
9
Progress in structure based drug design for G protein-coupled receptors.基于结构的G蛋白偶联受体药物设计进展。
J Med Chem. 2011 Jul 14;54(13):4283-311. doi: 10.1021/jm200371q. Epub 2011 Jun 15.
10
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.激动剂结合的腺苷 A2A 受体结构揭示了 G 蛋白偶联受体激活的共同特征。
Nature. 2011 May 18;474(7352):521-5. doi: 10.1038/nature10136.